活性氧
单宁酸
氧化应激
急性肾损伤
药理学
超氧化物歧化酶
肾
谷胱甘肽过氧化物酶
化学
程序性细胞死亡
生物化学
医学
细胞凋亡
内科学
有机化学
作者
J. Qin,Zepeng Li,Youyou Feng,Yingcong Guo,Zhenting Zhao,Shirui Sun,Zheng Jin,Mingzhen Zhang,Jing Zhang,Yilei Zhang,Jing Wei,Chenguang Ding,Wujun Xue
标识
DOI:10.1021/acsbiomaterials.4c00844
摘要
Acute kidney injury (AKI), predominantly associated with the excess production of endogenous ROS, is a serious renal dysfunction syndrome. Ferroptosis characterized by iron-dependent regulated cell death has significant involvement in AKI pathogenesis. As symptomatic treatment of AKI remains clinically limited, a new class of effective therapies has emerged, which is referred to as nanozyme. In our research, a natural mesoporous poly(tannic acid) nanosphere (referred to as PTA) was developed that can successfully mimic the activity of superoxide dismutase (SOD) by Mussel-inspired interface deposition strategy, for effective ROS scavenging and thus inhibition of ferroptosis to attenuate AKI. As anticipated, PTA mitigated oxidative stress and inhibited ferroptosis, as opposed to other modes of cell death such as pyroptosis or necrosis. Furthermore, PTA exhibited favorable biocompatibility and safeguarded the kidney against ferroptosis by enhancing the expression of SLC7a11/glutathione peroxidase 4(GPX4) and Nrf2/HO-1, while reducing the levels of ACSL4 protein in the ischemia and reperfusion injury (IRI)-induced AKI model. Moreover, PTA effectively suppressed aberrant expression of inflammatory factors. Overall, this study introduced antioxidative nanozymes in the form of mesoporous polyphenol nanospheres, showcasing exceptional therapeutic efficacy in addressing ROS-related diseases. This novel approach holds promise for clinical AKI treatment and broadens the scope of biomedical applications for nanozymes.
科研通智能强力驱动
Strongly Powered by AbleSci AI